GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

Haematologica. 2018 Feb;103(2):e78-e81. doi: 10.3324/haematol.2017.178996. Epub 2017 Oct 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / standards
  • B-Lymphocytes / drug effects*
  • Cell Death / drug effects*
  • Humans
  • Lymphocyte Depletion
  • Protein Engineering
  • Rituximab / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Rituximab
  • obinutuzumab